scispace - formally typeset
Search or ask a question
Author

Panos Kanavos

Bio: Panos Kanavos is an academic researcher from London School of Economics and Political Science. The author has contributed to research in topics: Health care & European union. The author has an hindex of 43, co-authored 228 publications receiving 6262 citations. Previous affiliations of Panos Kanavos include University of Barcelona & Technische Universität Darmstadt.


Papers
More filters
Journal ArticleDOI
TL;DR: In this article, the authors summarized the recent trends in the epidemiology and survival of cancers in the developing and developed world, and explored potential causes and policy responses to the disproportionate and growing cancer burden in less developed countries.

436 citations

Journal ArticleDOI
TL;DR: Whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs is discussed and a research agenda is outlined to help understand the societal value of orphan Drugs and issues surrounding their development, funding, and use.
Abstract: Historically, patients with rare diseases have been underserved by commercial drug development. In several jurisdictions, specific legislation has been enacted to encourage the development of drugs for rare diseases (orphan drugs), which would otherwise not be commercially viable. However, because of the small market, these drugs are often very expensive. Under the standard methods of health technology assessment (HTA) incorporating economic evaluation, orphan drugs do not usually prove to be cost-effective and this, coupled with their high cost, means that funding and patient access may be limited. However, these restrictions may not be in line with societal preferences. Therefore, this study discusses whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs and outlines a research agenda to help understand the societal value of orphan drugs and issues surrounding their development, funding, and use.

253 citations

Journal Article
TL;DR: In this article, the authors present a list of policy options for decision-makers in Central and Eastern European economies in transition, including generic drug marketing regulation, reference pricing, pricing of branded originator products, and the degree of price competition in pharmaceutical markets.
Abstract: Generic drugs have a key role to play in the efficient allocation of financial resources for pharmaceutical medicines. Policies implemented in the countries with a high rate of generic drug use, such as Canada, Denmark, Germany, the Netherlands, the United Kingdom, and the United States, are reviewed, with consideration of the market structures that facilitate strong competition. Savings in these countries are realized through increases in the volume of generic drugs used and the frequently significant differences in the price between generic medicines and branded originator medicines. Their policy tools include the mix of supply-side measures and demand-side measures that are relevant for generic promotion and higher generic use. On the supply-side, key policy measures include generic drug marketing regulation that facilitates market entry soon after patent expiration, reference pricing, the pricing of branded originator products, and the degree of price competition in pharmaceutical markets. On the demand-side, measures typically encompass influencing prescribing and dispensing patterns as well as introducing a co-payment structure for consumers/patients that takes into consideration the difference in cost between branded and generic medicines. Quality of generic medicines is a pre-condition for all other measures discussed to take effect. The paper concludes by offering a list of policy options for decision-makers in Central and Eastern European economies in transition.

200 citations

Journal ArticleDOI
TL;DR: Overall, cost evidence on rare diseases appears to be very scarce, with CF and Haemophilia being relatively well studied, compared to the other conditions, where very limited cost of illness information was available.

198 citations

01 Jan 2012
TL;DR: This report presents a meta-analysis of diabetes prevalence and policies in Europe over the past 25 years that concludes that diabetes prevalence in Europe is increasing, but the number of cases is still low compared to other European countries.
Abstract: 1 Executive summary 3 1. Background and Objectives 9 Background 9 1.1 Objectives 10 1.2 2. Methodology 11 2.1 Data sources and caveats 11 2.2.1 Precision of Prevalence 11 2.2.2 Direct costs 15 2.2.3 Cost of complications 16 2.2.4 Indirect costs 17 2.2.5 Process and outcome indicators 18 3. Diabetes Burden and Policies in Europe 21 3.1 Incidence 21 3.2 Diabetes prevalence 22 3.3 National Diabetes Programmes 25 3.3.1 France 26 3.3.2 Germany 27 3.3.3 Italy 27 3.3.4 Spain 28 3.3.5 United Kingdom 29 3.3.6 Overall 30 3.4 Conclusions 32

190 citations


Cited by
More filters
Book
23 Sep 2019
TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
Abstract: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.

21,235 citations

Journal ArticleDOI
TL;DR: Changing global incidence and mortality patterns for select common cancers and the opportunities for cancer prevention in developing countries are described.
Abstract: While incidence and mortality rates for most cancers (including lung, colorectum, female breast, and prostate) are decreasing in the United States and many other western countries, they are increasing in several less developed and economically transitioning countries because of adoption of unhealthy western lifestyles such as smoking and physical inactivity and consumption of calorie-dense food. Indeed, the rates for lung and colon cancers in a few of these countries have already surpassed those in the United States and other western countries. Most developing countries also continue to be disproportionately affected by cancers related to infectious agents, such as cervix, liver, and stomach cancers. The proportion of new cancer cases diagnosed in less developed countries is projected to increase from about 56% of the world total in 2008 to more than 60% in 2030 because of the increasing trends in cancer rates and expected increases in life expectancy and growth of the population. In this review, we describe these changing global incidence and mortality patterns for select common cancers and the opportunities for cancer prevention in developing countries.

2,577 citations

01 Jan 2016

1,538 citations